Virtu Financial LLC Takes $41,000 Position in Lipella Pharmaceuticals Inc. (NASDAQ:LIPO)

Virtu Financial LLC acquired a new position in Lipella Pharmaceuticals Inc. ( NASDAQ:LIPO – Free Report ) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,310 shares of the company’s stock, valued at approximately $41,000.

Lipella Pharmaceuticals Price Performance Shares of Lipella Pharmaceuticals stock opened at $2.57 on Wednesday. Lipella Pharmaceuticals Inc.



has a 1 year low of $2.02 and a 1 year high of $12.00.

The firm has a market cap of $3.11 million, a PE ratio of -0.60 and a beta of 0.

13. The company has a 50 day simple moving average of $2.88 and a two-hundred day simple moving average of $3.

02. Lipella Pharmaceuticals ( NASDAQ:LIPO – Get Free Report ) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($1.

19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $1.24.

The company had revenue of $0.17 million during the quarter. Lipella Pharmaceuticals had a negative net margin of 882.

82% and a negative return on equity of 192.33%. About Lipella Pharmaceuticals Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.

The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Featured Stories Want to see what other hedge funds are holding LIPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lipella Pharmaceuticals Inc.

( NASDAQ:LIPO – Free Report ). Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .

.